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Abstract
Recently, a large number of studies focus on (i) adipose tissue endocrine and para-
crine function, and (ii) adipose-immune interactions herein referred to as adipo-
immunology. In e!ect, a wide range of signaling proteins, dubbed adipokines, 
was identi"ed as endocrine and paracrine secretory products of adipocytes and 
associated stromal vascular cells, including macrophages, lymphocytes and mast 
cells, the latter being less evaluated as compare to the formers. During obesity 
immune cells migrate into adipose tissue and in#ame it by the secretion of a large 
amount of adipokines and thus trigger the development of so-called low grade 
in#ammation-related diseases. Based on Steve Galli’s concept of mast cell as master 
cells in many biological and pathological processes (New Engl J Meet 1993; 328:257-
265), here we highlight recent studies on the signi"cance of adipose mast cells in 
the pathogenesis and therapy of cardiometabolic diseases (atherosclerosis, obe-
sity, type 2 diabetes mellitus, metabolic syndrome) and breast cancer. Knowledge 
of the master work of these cells may provide a background for mast cell-targeted 
pharmacology for low grade in#ammation-related diseases. 
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Introduction
In the last 20 years there is an increasing 
attention to the adipobiology of various 
diseases, one of the most exciting exam-
ples being the rapidly growing interest 
in understanding the adipose tissue se-
cretion of multifunctional signaling pro-
teins collectively designated adipokines 
(1-3). ese molecules, via endocrine 
and paracrine way, are potent modula-
tors of many biological processes in-
cluding metabolism, in!ammation, im-
munity, vascular contractility, and cell 
proliferation (4-17).
Here we review current data of adipose 
tissue paracrine signaling in the patho-
genesis of low grade in!ammation-relat-
ed diseases, with special reference to the 
possible involvement of adipose mast 
cell’s secretion of mastokines (mast cell-
derived adipokines). is may provide 
basis of mast cell-targeted adipophar-
macology (18-22).
Adipose tissue
Adipose tissue is a cellular and extracel-
lular matrix assembly composed of adi-
pocytes, "broblasts, immune cells and 
matrix components, also rich in sym-
pathetic nerve "bers, blood vessels, and 
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stem cells.  In humans, particularly well developed is the white 
adipose tissue (WAT), a major metabolic and secretory organ. 
Human WAT is partitioned into two large depots (visceral and 
subcutaneous), and many small depots associated with vari-
ous organs, including heart, blood vessels, major lymph nodes, 
pancreas, ovaries, bone marrow, eyes, prostate, and mammary 
glands. White adipose tissue may grow and shrink dramatically 
to meet the energetic needs of an organism. However, severe 
metabolic and inammatory consequences can result from ex-
cessive WAT accumulation, featuring cardiometabolic diseases 
(CMD). Adipoimmunology of brown adipose tissue is out of the 
scope of present review.
Lean adipose tissue is populated with resident immune cells, 
which maintain tissue homeostasis through the secretion of 
adipokines that polarize adipose tissue macrophages (M) in an 
anti-inammatory phenotype, M2 state. Diet-induced obesity is 
associated with the loss of tissue homeostasis and development 
of type 1 inammatory responses in WAT expressed by pro-in-
ammatory M1 phenotype (5, 9, 12-15). 
Adipokines: new players in inammation and immunity
Celsus’s description (1st century AD) of inammation feature 
includes rubor et tumor cum calor et dolor. Inammation is an 
essential biological response aiming at recovering from injury, 
wound healing being a paradigm of such a homeostatic phe-
nomenon. However, what begins as a protective response, in 
excess becomes a damaging process, hence the inammation is 
increasingly recognized as the underlying basis of a signi!cant 
number of diseases. Recent genomic studies in human WAT re-
vealed that a panel of inammatory  molecules was upregulated 
in obese compared to lean subjects (2, 3). "ese molecules are 
secretory products of adipocytes and associated stromal vascu-
lar cells, including macrophages, lymphocytes and mast cells. 
Of note, calorie restriction diet improved the anti-inammatory 
pro!le of obese subjects via increase of anti-inammatory and 
decrease of pro-inammatory molecules. Further, weight loss 
resulted in decrease of adipose-associated immune cells and in-
creased production of anti-inammatory adpokines (7, 9-17). 
Such a sophisticated biology supports the hypothesis that adi-
pokines may indeed be potent modulators of low grade inam-
mation associated with atherosclerosis, obesity, type 2 diabetes, 
metabolic syndrome, inammatory bowel diseases, thyroid-
associated (Graves’) ophthalmopathy, breast cancer, and non-
alcoholic fatty liver disease, to list some of many examples (1, 
7, 9-18). Accordingly, the !eld of adipoimmunology of disease 
has attracted great attention, exempli!ed by the rapidly growing 
interest in understanding the adipose tissue protein secretion (4, 
5, 7, 22, 24-26). 
Mast cells
Mast cells were !rst described in 1878 by Paul Ehrlich (1854-
1915) in his doctoral thesis “Contribution to the "eory and 
Practice of Histological Staining” (4, 23 and references therein). 
Ehrlich observed that mast cells were commonly located in con-
nective tissue near blood vessels and nerves, as well as in in-
ammatory and tumor lesions. Mast cells are phenotypically 
and functionally versatile e#ector cells that have been tradition-
ally associated with the immunoglobulin E-mediated allergic 
response. However, recent studies implicate these cells in the 
regulation of inammation, !brosis, angiogenesis, hemostasis, 
cancerogenesis, and neuroimmune interactions (4, 7, 8, 18, 23-
28), which could associate with various low grade inammatory 
diseases. 
Adipose mast cells
Accumulating evidence demonstrates that the adipose mast cells 
could also be Galli’s master cells (also see 8) in the secretion of 
multifunctional biomolecules herein referred to as mastokines 
(mast cells-derived cytokines/adipokines; Table 1). "eir Yin-
Yang (4, 7), dual (8) regulatory activity should also be con-
sidered in adipoimmunology. At present, the study on adipo-
biology of mast cells is, however, limited as compared to that 
on other types of immune cells. PubMed search using the key 
words “adipose tissue and mast cells” up-regulates 162 articles 
in period between 1963 – December 2015, while “adipose tissue 
and macrophages” – 2539 articles,  “adipose and lymphocytes” 
- 1171 articles.
Table 1. Selected list of adipose-derived mastokines 
Leptin, IL-1, IL-4, TNF- , LIF, MCP-1 (CCL2), IL-8 (CXCL8),  
Eotaxin (CCL11)
RANTES (CCL5), FGF, TGF- , NGF, CNTF, MCSF, VEGF, HGF
Chymase, Tryptase, MMP, PAI-1, NO, VIP, Heparin, Histamine
Abbreviations: IL, interleukin; TNF-alpha,  Tumor Necrosis Factor- ; 
LIF, Leukemia Inhibitory Factor; MCP, Monocyte Chemoattractant 
Protein-1 (Cystein-Cystein modif Ligand); RANTES, Regulated on 
Activated Normal T-cell Expressed and Secreted; FGF, Fibroblast 
Growth Factor; TGF- , Transforming Growth Factor-beta; 
NGF, Nerve Growth Factor; CNTF, Ciliary Neurotrophic Factor; 
MCSF, Macrophage Colony-Stimulating Factor; VAGF, Vascular 
Endothelium Growth Factor; HGF, Hepatocyte Growth Factor; MMP, 
Matrix Metalloproteinase; PAI, plasminogen activator inhibitor; NO, 
nitric oxide; VIP, vasointestinal peptide
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Adipoimmunology of cardiometabolic disease
e possibility that the endocrine secretory activity of large adi-
pose depots may directly contribute to the altered blood levels 
of certain adipokines has recently gained considerable atten tion 
in studying obesity, type 2 diabetes and metabolic syndrome, 
examples of CMD (1, 7, 18, 24, 25, 29-31). Further, the parac-
rine sec retory activity of periadventitial adipose tissue has also 
become a focus in the pathobiology of another part of CMD – 
atherosclerosis and hypertension (18, 26-28). 
A long standing paradigm holds that the vascular wall is 
composed of three concentric tissue coats (tunicae): intima, 
media, and adventitia. However, large- and medium-sized ar-
teries, where usually atherosclerotic lesions develop, are consist-
ently surrounded by periadventitial adipose tissue, which was 
recently designated tunica adiposa (in brief, adiposa like intima, 
media, and adventitia) (26 and references therein). 
Neuro-immune-adipose interactions are illustrated in Figure 
1 (also see Fig. 2 for neuro-immune link). 
Figure 1. Schematic presentation of vascular wall composed 
of four tissue coats (tunicae): intima, media, adventitia, and 
adiposa. Arrows show that tunica media is a target for at least 
two vasorelaxing factors, endothelium-derived relaxing fac-
tor (EDRF) and adipocyte-derived relaxing factor (ADRF) re-
spectively. Discontinuous black line positioned at the adven-
titia-media border illustrates perivascular nerves. Small-sized 
discontinuous black lines located in tunica adiposa indicate 
adipose nerves. Black granules (except those linked to arrows) 
illustrate immune cells - their association with nerves and adi-
pocytes is also depicted. From (26).
Figure 2. Mast cells (MC) are source of and target for nerve 
growth factor (NGF). From (4; also see 24, 25, 38).
Adipoimmunology of breast cancer
It is known that in!ammation can promote tumorigenesis. ere 
is compelling evidence indicating that both normal mammary 
gland development and breast cancer growth depend, in part, 
on microenvironment, of which adipose tissue is a key compo-
nent. Adipose "broblasts are thus important cellular component 
of breast cancer microenvironment. ese cells, being bona !de 
steroidogenic cells, are one of the major extragonadal sources 
of estrogen secretion. Estrogen synthesis is mediated by the 
enzyme aromatase cytochrome P450 (CYP19) which converts 
androgens to estrogens. In breast cancer, one of the most aggres-
sive human cancer, intratumoral proliferation of breast adipose 
"broblasts is accompanied by an increased CYP19 expression 
by these cells, leading to proliferation of breast epithelial cells 
(7, 18 and references therein). Further, breast cancer commonly 
associates with a prominent immune, especially mast cell, re-
sponse. Notably, both adipocytes and mast cells produce various 
adipokines   known to upregulate aromatase expression. And, 
adipose- and mast cell-derived tryptase is a potent stimulator of 
"broblast proliferation (4) as well as a potent angiogenic factor 
(see 7, 18).   
A novel piece to the puzzle of breast cancer is that nerve 
growth factor (NGF), a neurotrophin known to be produced by 
mast cells (24, 25) as well as adipocytes (32), stimulates breast 
cancer cell proliferation (see 7, 18). Importantly, the antiestro-
gen drug tamoxifen inhibits NGF-mediated breast cancer cell 
proliferation through inhibition of the Trk-A receptor (see 7, 
18). ese data suggest a novel, NGF/mast cell-mediated mech-
anism in the action of an old drug, tamoxifen, in breast cancer 
pharmacotherapy. Together these "ndings open possibilities for 
an adipose NGF/mast cell-oriented therapy of breast cancer, and 
pressingly call for speci"c studies on both adipoimmunology 
and adipopharmacology of this neoplastic disorder. Noteworthy, 
an elegant study by Julio Celis and colleagues (33) provided the 
most extensive proteomic analysis of the mammary adipose se-
cretome in high risk breast cancer patients. 
Adipobiology 7, 2015
Adipose mast cells18 REVIEW
Coda
Adipose tissue is a major source of and target for inammatory 
and broproliferative signals, mast cells being their master pro-
ducer. It is worth concluding that adipocytes and mast cells both 
share several biological features in common: (i) they are bona 
!de  secretory cell types, (ii) they secrete  a wide range of same 
signaling molecules, and (iii) they are implicated in the patho-
biology of various low grade inammatory diseases. Further in-
vestigations aimed at pursuing cell-to-cell communications via 
adipose mast cell-derived extracellular vesicles (exosomes and 
ectosomes) (34-36) may bring a novel insight in adipoimmunol-
ogy. And may prove whether adipose mast cells stand indeed as 
a master in this research eld (8, 23-26, 37, 38).
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